about
sameAs
Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET ImagingPhase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.Tumor immunotargeting using innovative radionuclidesA pretargeting system for tumor PET imaging and radioimmunotherapyDifferences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data.What can be expected from nuclear medicine tomorrow?Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Pretargeting with the affinity enhancement system for radioimmunotherapy.99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonographyPrognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.Challenges in nuclear medicine: innovative theranostic tools for personalized medicineSyndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumorsClinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate CancerRevisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsImprovement of radioimmunotherapy using pretargeting.Current status and perspectives in peptide receptor radiation therapy.Immuno-PET for Clinical Theranostic Approaches.Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.Radiolabeled antibodies for cancer imaging and therapy.18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.Radioimmunoconjugates for the treatment of cancer.Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Radioimmunotherapy for Treatment of Acute Leukemia.Report of the 6th International Workshop on PET in lymphoma.Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine".Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.[Radiolabeled antibodies for cancer treatment].Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?
P50
Q26784016-2C38087F-8915-40D8-AA57-95E0CE2E63B4Q27853023-35E15B99-EF72-450F-8758-A4D044B59452Q28083230-73CB9B25-CE4F-4376-BE98-66E8EDBB50EBQ28087820-A4A139F9-0AA3-43F2-B158-EC1245220691Q30577117-56847277-50D1-47C1-8ABC-D70A9CE02EAFQ31095116-3C12BEC5-E309-439C-A744-C8E126C390F5Q33366818-EA22EE17-AEEB-4B5E-AFEE-0E4D833C3233Q33388981-0EDCD499-80EB-4FE0-AB8A-A077A2479B95Q33400076-9BD513AA-AB47-4AE0-9E7B-7D3BDF3ACF20Q33941046-524F09AD-C76C-48A3-B898-A0ED3360CF4AQ34242100-93F7A9F1-2EE8-443F-8132-E8242527D7DCQ34441785-03D1871B-0EC0-462D-9297-20BAB97CBA30Q34931319-AF669BA7-5A44-4B26-83AE-1A7894BE060DQ35104505-4B4FA1FD-B779-4A18-A506-09B7CFDB960CQ35650530-938B9CD7-F414-449D-BFAC-09618911ACB5Q35877090-575F3F1D-A40A-4D2A-8853-0FE329531705Q36039090-500B71B3-B6C2-4C53-AD1A-4A37F7BFB823Q36088862-2F0D8457-454F-4BC3-8BC6-D766C125FDA6Q36323585-D9F8EAB5-8730-4C32-BFD1-964DFE08D5EEQ36941931-D9BDD292-82F9-47E1-877D-DAD42D74350CQ37550887-F98D0F30-8D8D-4231-BDC6-8781193D16F3Q37631461-9F521C6B-D450-4176-BE69-34560E19D0B9Q37686447-1B07C0CB-F641-4A85-866C-D7B53A402808Q37691050-3288FD94-9EBF-4C83-8086-A80506D55872Q38036119-46014244-7C5C-4A50-863D-22D4A17D6803Q38146479-A0B58A54-98D7-4FA3-ABC2-528B3980DE39Q38273846-B0455A69-D2BC-4218-A015-2862A4A63B7AQ38691472-720E03D0-CDCB-46C2-A22C-16DFF732A584Q38742247-6B3B0416-49ED-49D8-8ADC-0E8BF79C5216Q38926460-3FDC9F22-50F5-45C1-8BFD-D9E160770D30Q38948546-A0BE59C7-4D04-4A94-A339-AB7B6FB7A7F1Q39361254-58533346-A584-4E33-94C2-796D93C85E79Q39519197-50AE6A50-BE63-4A6F-BE2B-5DE34C8BB695Q39744448-16A59383-AC27-4EDA-B635-8C1D4CBB7743Q39857869-60520440-C937-4E5F-8E08-7A52B3885968Q42238330-B06D56D1-4412-4389-B02A-D8A24293070CQ43080849-1E39ACA3-925C-4553-9049-4FBC7440CADDQ43122515-5D19551A-1E35-4E1C-BF85-F97CE096C46CQ43207441-241B8D63-F1DF-4C9A-A8BF-2126D68A7A4AQ43764750-E1F27717-31B4-47CE-A623-01FE1B068C38
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Françoise Kraeber-Bodéré
@ast
Françoise Kraeber-Bodéré
@en
Françoise Kraeber-Bodéré
@es
Françoise Kraeber-Bodéré
@sl
type
label
Françoise Kraeber-Bodéré
@ast
Françoise Kraeber-Bodéré
@en
Françoise Kraeber-Bodéré
@es
Françoise Kraeber-Bodéré
@sl
prefLabel
Françoise Kraeber-Bodéré
@ast
Françoise Kraeber-Bodéré
@en
Françoise Kraeber-Bodéré
@es
Françoise Kraeber-Bodéré
@sl
P214
P1053
F-7143-2013
P106
P21
P213
0000 0003 5805 1487
P214
P31
P3762
P3829
P496
0000-0002-3417-0759
P735
P7859
viaf-203889400